Mike Hassman

Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA.

C.W. Obel A/S provides investment services to industrial companies. The firm's financial assets are located in collaboration with independent financial advisor used by banks and pension companies. The company was founded by Christen Winther Obel in 1787 and is headquartered in Copenhagen, Denmark.

5AM Venture Management LLC (5AM Ventures) is an Independent Venture Capital firm founded in 2002 by Andrew J. Schwab, Carin M. Rollins and John D. Diekman. The firm is headquartered in San Francisco, US.

The Drug Information Association is a non-profit multidisciplinary association that operates to promote health and well-being. The non-profit company is based in Horsham, PA. Marwan Fathallah has been the CEO of the company since 2023.

The Food & Drug Law Institute is a nonprofit membership organization that provides education, training, publications, and professional engagement opportunities in the field of food and drug law. The non-profit company is based in Washington. The American company offers a platform for stakeholders to inform innovative public policy, law, and regulation. Christine M. Simmon has been the CEO of the company since 2022.

Juventas Therapeutics, Inc. provides regenerative therapies for cardiovascular disease. It is a clinical-stage biotechnology company developing a pipeline of factor-based regenerative therapies to treat life-threatening diseases. The company's product has been shown to protect and repair tissue following ischemic injury by recruiting the body's own stem cells to the damaged tissue. The company was founded by Rahul A. Aras and Marc S. Penn in 2007 and is headquartered in Cleveland, OH.

DySIS Medical Ltd. designs, develops, manufactures, and markets medical imaging systems. Its imaging systems assist clinicians with non-invasive, in-vivo detection of cancerous and pre-cancerous lesions and provides tools to aid medical practitioners in the detection, grading, and documentation of cervical neoplasia. The company was founded by Costas Balas in 2002 and is headquartered in Livingston, the United Kingdom.

Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA.

Cleave Biosciences, Inc. engages in the development of cancer drug products. The company was founded by Raymond J. Deshaies, Seth Cohen, Francesco Parlati, Peter A. Thompson and Laura K. Shawver in 2010 and is headquartered in San Francisco, CA.

PharmaLex GmbH engages in the provision of specialized services in the fields of development consulting, regulatory affairs, epidemiology and risk management, compliance, as well as quality management, particularly for the pharmaceutical, biotech, and medical device industries. These include providing technical and development support for product development, in-house management of clinical and analytical programs, establishment of pharmacology and regulatory services to ensure approval of pharmaceutical products in certain markets, development of decision-making tools for clinical trial recruitment, and study monitoring and program management. The company was founded in 1994 and is headquartered in Friedrichsdorf, Germany.

Grace Science Foundation is a biotechnology company that was founded in 2017 by Matt Wilsey and Dr. Carolyn Bertozzi. The private company is based in San Francisco, CA. The company focuses on developing novel therapies based on the function of NGLY1, a key enzyme involved in proteostasis. Grace Science Foundation's deep knowledge of the NGLY1 pathway enables them to identify new ways of treating NGLY1 deficiency as well as more common diseases.

Rallybio LLC operates as a development-stage biotechnology company. The firm develops transformative therapies for patients. It focuses on bringing life-transforming medicines to patients with devastating and rare disorder. The company was founded by Martin Mackay, Stephen Uden and Jeffrey Fryer in 2018 and is headquartered in Farmington, CT.

Rallybio Holdings LLC engages in the provision of healthcare services. The company is headquartered in New Haven, CT.

Abzu ApS provides technology services. It offers Abzu AI platform. The firm specializes in data, deep and machine learning, AI platform, cell based model, predictive problems and artificial general intelligence. The company was founded by Casper Skern Wilstrup in January 2018 and is headquartered in Copenhagen, Denmark.

Tiburio Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It provides novel treatments for rare neuroendocrine tumors and endocrine diseases. The company was founded by James Gregg McArthur in January 2019 and is headquartered in Cambridge, MA.

Ensoma, Inc. believes in the future of medicine and is committed to creating a new therapeutic category to tackle diseases that affect millions around the world, such as cancer and autoimmune disease, as well as inherited conditions. Ensoma is based in Boston, MA and has subsidiaries in Denmark. The company's engenious™ platform combines innovative delivery technology with the full DNA editing toolkit to address these disorders. Ensoma is supported by top-tier investors, a strategic collaboration with Takeda, and a passionate team. The company was founded by André Lieber, Hans-Peter Kiem, Kush M. Parmar, and the CEO is Emile F. Nuwaysir.

Immuneel Therapeutics Pvt Ltd. operates as a cancer treatment center. The company was founded by Kiran Mazumdar-Shaw, Kush M. Parmar and Siddhartha Mukherjee is headquartered in Bengaluru, India.

GlycoEra AG is a Swiss biotechnology company specializing in the development of novel biologics for various indications. The company is based in Schlieren, Switzerland, and the USA. The company utilizes its innovative customglycan platform to design, engineer, and develop medicines based on deep expertise in glycobiology. GlycoEra has raised over $49 million in a 2021 series A financing round co-led by 5AM Ventures, Sofinnova Partners, and Roche Venture Fund. The company was founded by Dominique Sirena, Amir Faridmoayer, and Veronica Gambillara Fonck. Ganesh Venkataraman Kaundinya has been the CEO of the company since 2020.

Rapport Therapeutics, Inc. engages in the discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. It develops the RAP (receptor associated proteins) technology platform. The company was founded by Steven M. Paul and David Bredt in February 2022 and is headquartered in Boston, MA.

Precede Biosciences is a company that aims to improve success rates in drug development and clinical practice by breaking down the barriers to precision medicine. The company is based in Boston, MA. The company seeks to redefine what can be learned from a simple blood draw to better target medicines to the right patients. Precede Biosciences is revolutionizing precision medicine by revealing unprecedented insights into disease-defining biology from a simple blood test. The CEO of the company is Rehan Verjee.

Novira Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It focuses on the discovery and development of therapies for the treatment of chronic hepatitis B (CHB) infection. The firm’s novel antiviral drug candidates addresses the limitations of CHB therapies. The company was founded in 2009 by Osvaldo Flores, Ali Munawar and George D. Hartman and is headquartered in Doylestown, PA.